ZA9811794B - Ace inhibitor-MMP inhibitor combinations. - Google Patents

Ace inhibitor-MMP inhibitor combinations.

Info

Publication number
ZA9811794B
ZA9811794B ZA9811794A ZA9811794A ZA9811794B ZA 9811794 B ZA9811794 B ZA 9811794B ZA 9811794 A ZA9811794 A ZA 9811794A ZA 9811794 A ZA9811794 A ZA 9811794A ZA 9811794 B ZA9811794 B ZA 9811794B
Authority
ZA
South Africa
Prior art keywords
inhibitor
combinations
mmp
ace
ace inhibitor
Prior art date
Application number
ZA9811794A
Other languages
English (en)
Inventor
Jr Joseph Thomas Peterson
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9811794(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA9811794B publication Critical patent/ZA9811794B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA9811794A 1997-12-23 1998-12-22 Ace inhibitor-MMP inhibitor combinations. ZA9811794B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23

Publications (1)

Publication Number Publication Date
ZA9811794B true ZA9811794B (en) 1999-06-29

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9811794A ZA9811794B (en) 1997-12-23 1998-12-22 Ace inhibitor-MMP inhibitor combinations.

Country Status (24)

Country Link
US (1) US6133304A (de)
EP (1) EP1047450B1 (de)
JP (1) JP2001526245A (de)
KR (1) KR20010033473A (de)
AR (1) AR015504A1 (de)
AT (1) ATE225187T1 (de)
AU (1) AU751701B2 (de)
BR (1) BR9814422A (de)
CA (1) CA2305436A1 (de)
CO (1) CO4970775A1 (de)
DE (1) DE69808518T2 (de)
DK (1) DK1047450T3 (de)
ES (1) ES2184340T3 (de)
HU (1) HUP0100427A3 (de)
IL (1) IL135428A0 (de)
IS (1) IS5446A (de)
NO (1) NO20003256D0 (de)
NZ (1) NZ503962A (de)
PE (1) PE20000065A1 (de)
PL (1) PL341335A1 (de)
PT (1) PT1047450E (de)
UY (1) UY25321A1 (de)
WO (1) WO1999032150A1 (de)
ZA (1) ZA9811794B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01008857A (es) * 1999-03-03 2002-07-02 Procter & Gamble Inhibidores de metaloproteasa dihetero sustituidos.
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
ATE530183T1 (de) 2001-01-29 2011-11-15 Ortho Mcneil Pharm Inc Substituierte indole und ihre verwendung als integrin-antagonisten
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
WO2003015762A1 (fr) * 2001-08-20 2003-02-27 Ono Pharmaceutical Co., Ltd. Agent therapeutique pour insuffisance cardiaque
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
EP1545287B1 (de) * 2002-10-04 2012-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Vasoregulierende verbindungen und anwendungsverfahren
AU2003295422B2 (en) * 2002-11-07 2009-01-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
CA2534352A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
PT1684719E (pt) * 2003-11-14 2012-02-03 Baxter Int Composições de alfa-1-antitripsina e métodos de tratamento utilizando estas composições
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
MX2007001337A (es) * 2004-08-02 2008-03-13 Genmedica Therapeutics Sl Compuestos para inhibir amina-oxidasas que contienen cobre y usos de los mismos.
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
CA2728766A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011041545A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
PH12017502049A1 (en) 2011-08-30 2018-08-29 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9884085B2 (en) 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
EP3169684B1 (de) 2014-07-17 2019-06-26 CHDI Foundation, Inc. Kombination des kmo inhibitors 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carbonsäure mit antiviralem wirkstoff zur behandlung von mit hiv zusammenhängenden neurologischen erkrankungen
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527879B1 (de) * 1990-05-11 1997-02-05 Pfizer Inc. Synergistische therapeutische zusammensetzungen und verfahren
CA2212713A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist
DE69707865T2 (de) * 1996-05-17 2002-05-02 Warner-Lambert Co., Morris Plains Biphenylsulfonamid matrix metalloproteinase inhibitoren
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
HUP0100427A3 (en) 2002-11-28
IS5446A (is) 2000-04-14
CA2305436A1 (en) 1999-07-01
AR015504A1 (es) 2001-05-02
BR9814422A (pt) 2000-10-10
NO20003256L (no) 2000-06-22
PE20000065A1 (es) 2000-02-11
DE69808518D1 (de) 2002-11-07
EP1047450B1 (de) 2002-10-02
CO4970775A1 (es) 2000-11-07
KR20010033473A (ko) 2001-04-25
UY25321A1 (es) 2004-07-30
US6133304A (en) 2000-10-17
EP1047450A1 (de) 2000-11-02
AU1522099A (en) 1999-07-12
PL341335A1 (en) 2001-04-09
NO20003256D0 (no) 2000-06-22
IL135428A0 (en) 2001-05-20
HUP0100427A2 (hu) 2001-06-28
DK1047450T3 (da) 2003-01-27
ATE225187T1 (de) 2002-10-15
PT1047450E (pt) 2003-02-28
ES2184340T3 (es) 2003-04-01
WO1999032150A1 (en) 1999-07-01
JP2001526245A (ja) 2001-12-18
AU751701B2 (en) 2002-08-22
NZ503962A (en) 2002-03-28
DE69808518T2 (de) 2003-06-26

Similar Documents

Publication Publication Date Title
ZA977969B (en) Reflux inhibitors.
ZA98376B (en) Sulfamide-metalloprotease inhibitors
ZA9811794B (en) Ace inhibitor-MMP inhibitor combinations.
GB2321641B (en) Sulfamide-metalloprotease inhibitors
IL131661A0 (en) Protease inhibitors
ZA988967B (en) Lactam metalloprotease inhibitors.
HK1016976A1 (en) Resorcinyl-triazine.
HUP0002247A3 (en) Protease inhibitors
IL132630A0 (en) Protease inhibitors
IL132629A0 (en) Protease inhibitors
ZA981926B (en) Detergent--package combination.
ZA987055B (en) Substituted 4-benzoylpyrazoles.
ZA987058B (en) Substituted 4-benzoylpyrazoles.
HK1017834A1 (en) Bodyshaper.
EP1015438A4 (de) Protease inhibitoren
ZA974779B (en) Thrombin inhibitors.
ZA977209B (en) Thrombin inhibitors.
ZA983705B (en) Pregnan-3-ol-20-ones.
ZA987B (en) Substituted 4-benzoylpyrazoles.
GB9815925D0 (en) HIV Intergrase inhibitors
EP0975612A4 (de) Proteaseinhibitoren
ZA992106B (en) Statin-MMP inhibitor combinations.
ZA981309B (en) 4-aminoalkoxy-1H-benzoimidazoles.
ZA983795B (en) Substituted 4-benzoyl-pyrazoles.
SI1047450T1 (en) Ace inhibitor-mmp inhibitor combinations